Skip to main content
Erschienen in: Herz 2/2014

01.03.2014 | e-Herz: Original article

Haplotype analysis of PPARγ C681G and intron CT variants

Positive association with essential hypertension

verfasst von: Q. Zhu, Z. Guo, X. Hu, M. Wu, Q. Chen, W. Luo, J. Liu

Erschienen in: Herz | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

There is strong evidence suggesting an association between the peroxisome-activated receptor γ (PPARγ) gene and multimetabolic disorders. The association of PPARγ genetic variants with essential hypertension (EH) has not yet been investigated. The aim of this study was to investigate the association between the PPARγ gene (C681G and intron CT) and EH, examining the polymorphism and haplotype in a Han Chinese population.

Methods

Participants were recruited within the framework of the PMMJS cohort population survey in an urban community of Jiangsu Province, China. Two single-nucleotide polymorphisms (SNPs) previously reported to be associated with multimetabolic disorders and the reasonable coverage of the PPARγ gene region were analyzed with TaqMan SNP genotyping assays.

Results

C681G and intron CT were significantly associated with an increased risk of EH both in the codominant model and the dominant model after adjusting for potential nongenetic risk factors. Analysis of the haplotype association revealed that the risk of EH was significantly increased among individuals carrying the GC (odds ratio, 95 % CI: 1.60, 1.21–2.11), CT (1.45, 1.03–2.11), and GT haplotypes (1.95, 1.17–3.23) compared with those carrying the CC haplotype.

Conclusion

The polymorphisms of C681G and intron CT were significantly associated with the risk of EH, and the GC, CT, and GT haplotypes established by C681G and intron CT are likely to be genetic markers of EH in the Han Chinese population.
Literatur
1.
Zurück zum Zitat Benkirane K, Viel EC, Amiri F et al (2006) Peroxisome proliferator-activated receptorg regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47:102–108PubMedCrossRef Benkirane K, Viel EC, Amiri F et al (2006) Peroxisome proliferator-activated receptorg regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47:102–108PubMedCrossRef
2.
Zurück zum Zitat Sourij H, Zweiker R, Wascher TC (2006) Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 29:1039–1045PubMedCrossRef Sourij H, Zweiker R, Wascher TC (2006) Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 29:1039–1045PubMedCrossRef
3.
Zurück zum Zitat Sidhu JS, Kaposzta Z, Markus HS et al (2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24:930–934PubMedCrossRef Sidhu JS, Kaposzta Z, Markus HS et al (2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24:930–934PubMedCrossRef
4.
Zurück zum Zitat Haffner SM, Greenberg AS, Weston WM et al (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684PubMedCrossRef Haffner SM, Greenberg AS, Weston WM et al (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684PubMedCrossRef
5.
Zurück zum Zitat Leibovitz E, Schiffrin EL (2007) PPAR activation: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 50:120–125PubMedCrossRef Leibovitz E, Schiffrin EL (2007) PPAR activation: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 50:120–125PubMedCrossRef
6.
Zurück zum Zitat Laforet M, Froelich N, Parissiadis A et al (1997) An intronic mutation responsible for a low level of expression of an HLA-A*24 allele. Tissue Antigens 50:340–346PubMedCrossRef Laforet M, Froelich N, Parissiadis A et al (1997) An intronic mutation responsible for a low level of expression of an HLA-A*24 allele. Tissue Antigens 50:340–346PubMedCrossRef
7.
Zurück zum Zitat Seber S, Ucak S, Basat O et al (2006) The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 71:52–58PubMedCrossRef Seber S, Ucak S, Basat O et al (2006) The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 71:52–58PubMedCrossRef
8.
Zurück zum Zitat Oliver WR, Shenk JL, Snaith MR et al (2001) A selective peroxisome proliferator -activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98:5306–5311PubMedCentralPubMedCrossRef Oliver WR, Shenk JL, Snaith MR et al (2001) A selective peroxisome proliferator -activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98:5306–5311PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Gallicchio L, Kalesan B, Huang HY et al (2008) Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. PPAR Res 81:1–9CrossRef Gallicchio L, Kalesan B, Huang HY et al (2008) Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. PPAR Res 81:1–9CrossRef
10.
Zurück zum Zitat Zhou H, Guo ZR, Yu LG et al (2010) Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. Diabetes Res Clin Pract 90:319–325PubMedCrossRef Zhou H, Guo ZR, Yu LG et al (2010) Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. Diabetes Res Clin Pract 90:319–325PubMedCrossRef
11.
Zurück zum Zitat Ding Y, Guo ZR, Wu M et al (2012) Gene-gene interaction between PPARδ and PPARγ is associated with abdominal obesity in a Chinese population. J Genet Genomics 39:625–631PubMedCrossRef Ding Y, Guo ZR, Wu M et al (2012) Gene-gene interaction between PPARδ and PPARγ is associated with abdominal obesity in a Chinese population. J Genet Genomics 39:625–631PubMedCrossRef
12.
Zurück zum Zitat World Health Organization (1999) International society of hypertension guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 17:151–183 World Health Organization (1999) International society of hypertension guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 17:151–183
13.
Zurück zum Zitat Meirhaeghe A, Fajas L, Helbecque N et al (1998) A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7:435–440PubMedCrossRef Meirhaeghe A, Fajas L, Helbecque N et al (1998) A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7:435–440PubMedCrossRef
14.
Zurück zum Zitat Meirhaeghe A, Fajas L, Gouilleux F et al (2003) A functional polymorphism in a STAT5b site of the human PPAR 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol 23:289–294PubMedCrossRef Meirhaeghe A, Fajas L, Gouilleux F et al (2003) A functional polymorphism in a STAT5b site of the human PPAR 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol 23:289–294PubMedCrossRef
15.
Zurück zum Zitat Touyz RM, Schiffrin EL (2004) Reactive oxygen species in vascular biology: implications in hyper tension. Histochem Cell Biol 122:339–352PubMedCrossRef Touyz RM, Schiffrin EL (2004) Reactive oxygen species in vascular biology: implications in hyper tension. Histochem Cell Biol 122:339–352PubMedCrossRef
16.
Zurück zum Zitat Yosefy C, Magen E, Kiselevich A et al (2004) Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 44:215–222PubMedCrossRef Yosefy C, Magen E, Kiselevich A et al (2004) Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 44:215–222PubMedCrossRef
17.
Zurück zum Zitat Benkirane K, Viel EC, Amiri F et al (2006) Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen -activated protein kinase in blood vessels in vivo. Hypertension 47:102–108PubMedCrossRef Benkirane K, Viel EC, Amiri F et al (2006) Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen -activated protein kinase in blood vessels in vivo. Hypertension 47:102–108PubMedCrossRef
18.
Zurück zum Zitat Buchanan TA, Meehan WP, Jeng YY et al (1995) Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96:354–360PubMedCentralPubMedCrossRef Buchanan TA, Meehan WP, Jeng YY et al (1995) Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96:354–360PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Itoh H, Doi K, Tanaka T et al (1999) Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor-gamma. Clin Exp Pharmacol Physiol 26:558–560PubMedCrossRef Itoh H, Doi K, Tanaka T et al (1999) Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor-gamma. Clin Exp Pharmacol Physiol 26:558–560PubMedCrossRef
20.
Zurück zum Zitat Bernobich E, De-Angelis L, Lerin C et al (2002) The role of the angiotension system in cardiac glucose homeostasis: thetapeutic implications. Drugs 62:1295–1314PubMedCrossRef Bernobich E, De-Angelis L, Lerin C et al (2002) The role of the angiotension system in cardiac glucose homeostasis: thetapeutic implications. Drugs 62:1295–1314PubMedCrossRef
21.
Zurück zum Zitat Calnek DS, Mazzella L, Roser S et al (2003) Peroxisome proliferator- activated receptor gamma ligands increase release of nitric oxide form endothelial cells. Arterioscler Thromb Vasc Biol 23:52–57PubMedCrossRef Calnek DS, Mazzella L, Roser S et al (2003) Peroxisome proliferator- activated receptor gamma ligands increase release of nitric oxide form endothelial cells. Arterioscler Thromb Vasc Biol 23:52–57PubMedCrossRef
22.
Zurück zum Zitat Kotchen TA, Zhang HY, Reddy S et al (1996) Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 270:660–666 Kotchen TA, Zhang HY, Reddy S et al (1996) Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 270:660–666
23.
Zurück zum Zitat Martin ER, Lai EH, Gilbert JR et al (2000) SNPing away at complex disease: analysis of singe-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet 67:383–394PubMedCentralPubMedCrossRef Martin ER, Lai EH, Gilbert JR et al (2000) SNPing away at complex disease: analysis of singe-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet 67:383–394PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Ma HX, Xu L, Yuan J et al (2007) Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics 17:417–423PubMedCrossRef Ma HX, Xu L, Yuan J et al (2007) Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics 17:417–423PubMedCrossRef
Metadaten
Titel
Haplotype analysis of PPARγ C681G and intron CT variants
Positive association with essential hypertension
verfasst von
Q. Zhu
Z. Guo
X. Hu
M. Wu
Q. Chen
W. Luo
J. Liu
Publikationsdatum
01.03.2014
Verlag
Urban & Vogel
Erschienen in
Herz / Ausgabe 2/2014
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-013-3819-x

Weitere Artikel der Ausgabe 2/2014

Herz 2/2014 Zur Ausgabe

e-Herz: Case study

Narrow QRS tachycardia

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.